Cross Country Healthcare heads into its May 7 earnings report with short sellers firmly in retreat and a stock that has quietly rebuilt from its March lows.
The defining story here is the scale of short covering. Short interest has been cut roughly in half since late March — dropping from nearly 5% of free float to around 3.1% now. At the peak in early April, estimated shares short topped 2 million; today that figure is below 925,000. That is an unusually rapid unwind for a mid-size healthcare services name, and it tracks almost precisely with the stock's recovery from $7.95 to $10.27. The covering has done most of the mechanical lifting on the price, suggesting the move higher is at least partially a function of position adjustment rather than fresh conviction buying.
The lending market reflects how much the squeeze potential has faded. Availability is ample — the borrow market is far from tight — and cost to borrow has collapsed to around 0.49%, down more than 75% from levels seen just a week earlier. That spike on April 21 (briefly touching 2.0%) appears to have been a short-lived dislocation rather than a structural tightening. With the short score sitting at 35 and drifting lower all month, the ORTEX composite reading confirms the bearish positioning is unwinding rather than rebuilding. Options traders are essentially neutral: the put/call ratio is 0.70, barely a quarter of a standard deviation above its 20-day average, and nowhere near the defensive posturing you would expect ahead of a genuinely contested print.
Analyst sentiment has improved meaningfully since the stock's early-year lows. Wedbush upgraded to Outperform in mid-March with a $15 target, and Benchmark moved to Buy with a $14 target in early March — both upgrades coming in direct response to the March 4 earnings print, which produced a 10% next-day gain and an 8.9% five-day follow-through. The consensus now sits at Hold, with two Outperform-equivalent ratings and five Holds — an improvement on the more heavily bearish profile from late 2025, when UBS was cutting targets and Barrington was downgrading. On valuation, the EV/EBITDA multiple is running near 7.3x and has eased modestly over the past month. The price-to-book is essentially at 1x — suggesting the market is assigning almost no premium to franchise value — while the PE sits elevated at 67x on what is still a recovering earnings base. EPS momentum scores are notably strong, ranking in the 95th percentile on a 90-day basis, though the 1-year forward EPS growth estimate ranks in only the 39th percentile — so momentum is catching up, but the absolute trajectory is still modest.
On the ownership side, the picture is quietly constructive. Boston Partners added roughly 646,000 shares in Q1, a sizable new build. Vanguard added 81,000. Kevin Clark holds nearly 953,000 shares and added 139,000 in the quarter. These are not activist moves, but they point to steady accumulation at current levels. The insider activity on March 31 tells a more prosaic story: a cluster of small routine sells by the CFO, General Counsel, and Group President at $9.40 — typical tax-withholding transactions on vested shares, given the uniform price and date, and all scored at minimal significance.
The one concrete historical data point worth noting: the last earnings print on March 4 delivered a 10% single-day gain, with the stock holding most of that into the five-day close (+8.9%). That was the catalyst that triggered both short covering and the wave of analyst upgrades. The next release on May 7 arrives with the stock trading 9% above that post-earnings level and a much lighter short base — meaning there is less mechanical fuel available to amplify a positive surprise the way the March print did. Peers were broadly weaker on the week: AMN closed flat (+1.2%) while ARDT and INFU slid 2.2% and 5.6% respectively, suggesting healthcare staffing as a group faces ongoing demand headwinds that the short covering in CCRN has, so far, papered over.
The May 7 print becomes the first real test of whether the fundamental improvement story — which the analyst upgrades and EPS momentum scores are pricing in — has staying power beyond the mechanics of short covering.
See the live data behind this article on ORTEX.
Open CCRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
